Papers in Blood Cancer Discovery
Page 3 · newest first
- New Insights into the Role of Clonotypic B Cells in Plasma-cell NeoplasiaBlood Cancer Discovery · 2026
- RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBlood Cancer Discovery · 2026
- Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2026
- Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid LeukemiaBlood Cancer Discovery · 2026
- Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2026
- Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic ApproachesBlood Cancer Discovery · 2026
- Highlighted Research ArticlesBlood Cancer Discovery · 2026
- A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaBlood Cancer Discovery · 2026
- Outstanding Questions to Understand and Target Splicing Factor–Mutant Blood CancersBlood Cancer Discovery · 2026
- Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort ZoneBlood Cancer Discovery · 2026
- MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaBlood Cancer Discovery · 2026
- CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular TherapyBlood Cancer Discovery · 2026
- 3D chromosome remodeling in B-cell development and acute lymphoblastic leukemiaBlood Cancer Discovery · 2026
- Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialBlood Cancer Discovery · 2026
- Genomic Insights into the Biology of T-lineage Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2026
- Models, Models, Everywhere: But Which One Should Guide Care?Blood Cancer Discovery · 2026
- Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALLBlood Cancer Discovery · 2026
- Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapyBlood Cancer Discovery · 2026
- Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T CellsBlood Cancer Discovery · 2026
- Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersBlood Cancer Discovery · 2026
- Reading the “T” Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple MyelomaBlood Cancer Discovery · 2026
- Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaBlood Cancer Discovery · 2026
- Highlighted Research ArticlesBlood Cancer Discovery · 2026
- The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic OpportunitiesBlood Cancer Discovery · 2026
- Multiplexed imaging reveals immune-metabolic niches in multiple myeloma linked to progression and bone diseaseBlood Cancer Discovery · 2026
- Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyBlood Cancer Discovery · 2026
- Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II studyBlood Cancer Discovery · 2026
- Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsBlood Cancer Discovery · 2026
- Remodeling of Mitochondrial Networks: Cellular Adaptation and Microenvironmental Reprogramming in Hematologic MalignanciesBlood Cancer Discovery · 2026
- First-line Therapy in Newly Diagnosed Multiple MyelomaBlood Cancer Discovery · 2026
- Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based CombinationsBlood Cancer Discovery · 2026
- A Triumvirate of Transformation: Oncogene, Ontogeny, and PlasticityBlood Cancer Discovery · 2026
- Seeing Is Believing: IEC-HS after CAR T CellsBlood Cancer Discovery · 2026
- Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsBlood Cancer Discovery · 2026
- Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic LeukemiaBlood Cancer Discovery · 2026
- Expectations and Limitations of Artificial Intelligence in Blood Cancer DiagnosisBlood Cancer Discovery · 2026
- No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk MyelomaBlood Cancer Discovery · 2025
- (Sub)Clonal Wars: IFN Interference Yields the Upper HandBlood Cancer Discovery · 2025
- Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβBlood Cancer Discovery · 2025
- Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaBlood Cancer Discovery · 2025
- Human TET2-mutant clonal hematopoiesis expansion is driven by distinct inflammatory signaling responses in stem cells versus myeloid progeny.Blood Cancer Discovery · 2025
- Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic LeukemiaBlood Cancer Discovery · 2025
- Nuclear Export Gone Rogue: XPO1’s Chromatin Side Hustle Fuels LeukemiaBlood Cancer Discovery · 2025
- Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in LymphomaBlood Cancer Discovery · 2025
- Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in LymphomaBlood Cancer Discovery · 2025
- Nuclear Export Gone Rogue: XPO1’s Chromatin Side Hustle Fuels LeukemiaBlood Cancer Discovery · 2025
- Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentBlood Cancer Discovery · 2025
- Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor MicroenvironmentBlood Cancer Discovery · 2025
- The Global State of Blood Cancers: An Ongoing ChallengeBlood Cancer Discovery · 2025
- The Link between Modifiable Risk Factors and Myeloid Disorders—From Plate to PathogenesisBlood Cancer Discovery · 2025